The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | The evolving treatment landscape for MZL: a shift toward targeted therapies
Fernando Martin-Moro, MD, Ramón & Cajal University Hospital, Madrid, Spain, comments on the evolving treatment landscape for marginal zone lymphoma (MZL), noting a shift away from chemotherapy combinations and toward targeted therapies. Dr Martin-Moro highlights the promise of combinations featuring BTK inhibitors, BCL2 inhibitors, and T-cell engagers. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Marginal zone lymphoma is an indolent lymphoma which is going to receive different lines of therapy and I think we are moving to less chemotherapy combinations and chemotherapy is less used. I mean we have targeted therapies, we are going to have chemo-free combinations, so I think we are moving to best schedules with less toxicity for our patients and with better responses...
Marginal zone lymphoma is an indolent lymphoma which is going to receive different lines of therapy and I think we are moving to less chemotherapy combinations and chemotherapy is less used. I mean we have targeted therapies, we are going to have chemo-free combinations, so I think we are moving to best schedules with less toxicity for our patients and with better responses. The combinations with BTK inhibitors are very promising, with BCL2 inhibitors sonroctoclax, venetoclax even, and also T-cell engagers, CAR T-cells, bispecifics that are also promising in this setting.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
